Rezolute FY26 net loss widens 4.26% to $77.59 million; FY26 G&A expenses climb 58.79% to $29.17 million
Bitget2026/09/24 20:06- Rezolute posted a fiscal 2026 net loss of USD 77.59 million, widening from USD 74.41 million a year earlier.
- R&D expense fell 12.56% to USD 53.8 million, and the company attributed the drop mainly to lower ersodetug manufacturing costs.
- G&A expense climbed 58.8% to USD 29.17 million, which it linked to higher stock-based compensation and pre-commercial professional fees.
- Cash, cash equivalents and marketable securities totaled USD 107.8 million at June 30, 2026, down from USD 167.9 million.
- Phase 3 upLIFT tumor HI study enrollment continues, with topline results expected before end-2026; sunRIZE congenital HI data remain under FDA review.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Anthropic "accidentally" leaks IPO documents! Plans to raise $69.3 billion, valuation drops from 2 trillion to 1.3 trillion
Anthropic mistakenly published and then withdrew a prospectus for a planned $69.3 billion fundraising, with its valuation dropping from a peak of $2 trillion to between $1.1 trillion and $1.3 trillion.
Subaru Publishes Transcript of First-Half FYE 2027 Financial Results Presentation
Citi: Occidental Petroleum (OXY.US) Q3 cash flow surpasses expectations, accelerated debt repayment cannot hide concerns over Q4 output
Citi published a research report maintaining Occidental Petroleum's "Neutral" rating, with a target price of $65.
WikiLeaks Founder Julian Assange Welcomes Daughter With Terminator Quote
Crypto prices
More
